Suchergebnisse - "Banach, Maciej"

PubPharm (61)

1

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD) : A position paper from the International Lipid Expert Panel (ILEP)

enthalten in: Pharmacological research | 2023

von Rizzo, M. | Colletti, A. | Penson, P. | +96

2

Coffee or tea : Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention

enthalten in: Pharmacological research | 2023

von Surma, S. | Sahebkar, A. | Banach, M.

3

Prevalence of statin intolerance : a meta-analysis

enthalten in: European heart journal | 2022

von Bytyçi, I. | Penson, P. | Mikhailidis, D. | +10

CommentIn: Eur Heart J. 2022 Mar 23;:. - PMID 35325103

4

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients : a position paper from the International Lipid Expert Panel (ILEP)

enthalten in: Journal of cachexia, sarcopenia and muscle | 2022

von Penson, P. | Bruckert, E. | Marais, D. | +100

5

A comprehensive review on the lipid and pleiotropic effects of pitavastatin

enthalten in: Progress in lipid research | 2021

von Sahebkar, A. | Kiaie, N. | Gorabi, A. | +5

6

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe : DA VINCI observational study

enthalten in: Atherosclerosis | 2021

von Vrablik, M. | Seifert, B. | Parkhomenko, A. | +8

7

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care : the DA VINCI study

enthalten in: European journal of preventive cardiology | 2021

von Ray, K. | Molemans, B. | Schoonen, W. | +28

8

Nutraceuticals in the Management of Dyslipidemia : Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?

enthalten in: Current atherosclerosis reports | 2021

von Cicero, A. | Fogacci, F. | Stoian, A. | +5

9

Impact of nutraceuticals on markers of systemic inflammation : Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP)

enthalten in: Progress in cardiovascular diseases | 2021

von Ruscica, M. | Penson, P. | Ferri, N. | +87

10

How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors

enthalten in: Progress in cardiovascular diseases | 2021

von Cybulska, B. | Kłosiewicz-Latoszek, L. | Penson, P. | +4

1
2
3
4
5
6
7
Nächster »
[7]